U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07639138) titled 'Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC' on June 05.
Brief Summary: This is a prospective, single-arm, investigator-initiated clinical study designed to evaluate the safety and efficacy of lenalidomide in combination with targeted therapy and immunotherapy in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after multiple lines of systemic treatment.
Eligible patients must have received at least two prior lines of systemic therapy, including both targeted therapy and immune checkpoint inhibitor (ICI)-based treatment, and must have previously achieved clin...